Literature DB >> 29778263

Hepatitis C Virus Elimination in the Human Immunodeficiency Virus-Coinfected Population: Leveraging the Existing Human Immunodeficiency Virus Infrastructure.

Meredith E Clement1, Lauren F Collins2, Julius M Wilder3, Michael Mugavero4, Taryn Barker5, Susanna Naggie6.   

Abstract

The objective of this review is to consider how existing human immunodeficiency virus (HIV) infrastructure may be leveraged to inform and improve hepatitis C virus (HCV) treatment efforts in the HIV-HCV coinfected population. Current gaps in HCV care relevant to the care continuum are reviewed. Successes in HIV treatment are then applied to the HCV treatment model for coinfected patients. Finally, the authors give examples of HCV treatment strategies for coinfected patients in both domestic and international settings.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Care cascade; Care continuum; Coinfection; Elimination; Hepatitis C infection; Human immunodeficiency virus

Mesh：

Substances：

Year:  2018        PMID： 29778263      PMCID： PMC6592269          DOI： 10.1016/j.idc.2018.02.005

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN： 0891-5520            Impact factor:   5.982


  94 in total

1.  Possible autoimmune thrombocytopenia associated with pegylated interferon-alpha2a plus ribavarin treatment for hepatitis C.

Authors:  Bruno C Medeiros; Paul A Seligman; Gregory T Everson; Lisa M Forman
Journal:  J Clin Gastroenterol       Date:  2004-01       Impact factor: 3.062

2.  Residual risk of transfusion in Ghana.

Authors:  D Candotti; F Sarkodie; J P Allain
Journal:  Br J Haematol       Date:  2001-04       Impact factor: 6.998

3.  Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.

Authors:  Fabrice Carrat; Firouzé Bani-Sadr; Stanislas Pol; Eric Rosenthal; Françoise Lunel-Fabiani; Asmae Benzekri; Patrice Morand; Cécile Goujard; Gilles Pialoux; Lionel Piroth; Dominique Salmon-Céron; Claude Degott; Patrice Cacoub; Christian Perronne
Journal:  JAMA       Date:  2004-12-15       Impact factor: 56.272

4.  Adherence to protease inhibitor therapy and outcomes in patients with HIV infection.

Authors:  D L Paterson; S Swindells; J Mohr; M Brester; E N Vergis; C Squier; M M Wagener; N Singh
Journal:  Ann Intern Med       Date:  2000-07-04       Impact factor: 25.391

5.  Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group.

Authors:  Y Benhamou; M Bochet; V Di Martino; F Charlotte; F Azria; A Coutellier; M Vidaud; F Bricaire; P Opolon; C Katlama; T Poynard
Journal:  Hepatology       Date:  1999-10       Impact factor: 17.425

6.  Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection.

Authors:  O Lesens; M Deschênes; M Steben; G Bélanger; C M Tsoukas
Journal:  J Infect Dis       Date:  1999-05       Impact factor: 5.226

7.  The association of health-care use and hepatitis C virus infection in a random sample of urban slum community residents in southern India.

Authors:  Melissa A Marx; K G Murugavel; Sudha Sivaram; P Balakrishnan; Mark Steinhoff; S Anand; David L Thomas; Suniti Solomon; David D Celentano
Journal:  Am J Trop Med Hyg       Date:  2003-02       Impact factor: 2.345

8.  Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment.

Authors:  Catherine A Fleming; Donald E Craven; David Thornton; Sheila Tumilty; David Nunes
Journal:  Clin Infect Dis       Date:  2002-12-11       Impact factor: 9.079

9.  Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.

Authors:  Francesca J Torriani; Maribel Rodriguez-Torres; Jürgen K Rockstroh; Eduardo Lissen; Juan Gonzalez-García; Adriano Lazzarin; Giampiero Carosi; Joseph Sasadeusz; Christine Katlama; Julio Montaner; Hoel Sette; Sharon Passe; Jean De Pamphilis; Frank Duff; Uschi Marion Schrenk; Douglas T Dieterich
Journal:  N Engl J Med       Date:  2004-07-29       Impact factor: 91.245

10.  Pegylated interferon alpha2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.

Authors:  Leonor Moreno; Carmen Quereda; Ana Moreno; María J Perez-Elías; Antonio Antela; José L Casado; Fernando Dronda; Maria L Mateos; Rafael Bárcena; Santiago Moreno
Journal:  AIDS       Date:  2004-01-02       Impact factor: 4.177
View more
  7 in total

1.  A Randomized Controlled Trial of Cash Incentives or Peer Support to Increase HCV Treatment for Persons With HIV Who Use Drugs: The CHAMPS Study.

Authors:  Kathleen M Ward; Oluwaseun Falade-Nwulia; Juhi Moon; Catherine G Sutcliffe; Sherilyn Brinkley; Taryn Haselhuhn; Stephanie Katz; Kayla Herne; Lilian Arteaga; Shruti H Mehta; Carl Latkin; Robert K Brooner; Mark S Sulkowski
Journal:  Open Forum Infect Dis       Date:  2019-04-09       Impact factor: 3.835

2.  Care Facilitation Advances Movement Along the Hepatitis C Care Continuum for Persons With Human Immunodeficiency Virus, Hepatitis C, and Substance Use: A Randomized Clinical Trial (CTN-0064).

Authors:  Lisa R Metsch; Daniel J Feaster; Lauren K Gooden; Carmen Masson; David C Perlman; Mamta K Jain; Tim Matheson; C Mindy Nelson; Petra Jacobs; Susan Tross; Louise Haynes; Gregory M Lucas; Jonathan A Colasanti; Allan Rodriguez; Mari-Lynn Drainoni; Georgina Osorio; Ank E Nijhawan; Jeffrey M Jacobson; Meg Sullivan; David Metzger; Pamela Vergara-Rodriguez; Ronald Lubelchek; Rui Duan; Jacob N Batycki; Abigail G Matthews; Felipe Munoz; Eve Jelstrom; Raul Mandler; Carlos Del Rio
Journal:  Open Forum Infect Dis       Date:  2021-06-27       Impact factor: 4.423

3.  Low Utilization of Direct-Acting Antiviral Agents in a Large National Cohort of HIV and HCV Coinfected Medicare Patients in the United States: Implications for HCV Elimination.

Authors:  Ping Du; Jeah Jung; Yamini Kalidindi; Kevin Farrow; Thomas Riley; Cynthia Whitener
Journal:  J Public Health Manag Pract       Date:  2022 Mar-Apr 01

4.  Cost of Hepatitis C care facilitation for HIV/Hepatitis C Co-infected people who use drugs.

Authors:  Sarah Gutkind; Laura E Starbird; Sean M Murphy; Paul A Teixeira; Lauren K Gooden; Tim Matheson; Daniel J Feaster; Mamta K Jain; Carmen L Masson; David C Perlman; Carlos Del Rio; Lisa R Metsch; Bruce R Schackman
Journal:  Drug Alcohol Depend       Date:  2022-01-10       Impact factor: 4.852

5.  Evaluation of the hepatitis C cascade of care among people living with HIV in New South Wales, Australia: A data linkage study.

Authors:  Samira Hosseini-Hooshyar; Maryam Alavi; Marianne Martinello; Heather Valerio; Shane Tillakeratne; Gail V Matthews; Gregory J Dore
Journal:  J Viral Hepat       Date:  2022-02-25       Impact factor: 3.517

6.  Barriers to hepatitis C direct-acting antiviral therapy among HIV/hepatitis C virus-coinfected persons.

Authors:  Lauren P Jatt; Malini M Gandhi; Rong Guo; Adam Sukhija-Cohen; Debika Bhattacharya; Chi-Hong Tseng; Kara W Chew
Journal:  J Gastroenterol Hepatol       Date:  2020-09-08       Impact factor: 4.029

7.  Hepatitis C continuum of care: Experience of integrative hepatitis C treatment within a human immunodeficiency virus clinic in Indonesia.

Authors:  Evy Yunihastuti; Rahmat Hariyanto; Andri Sanityoso Sulaiman; Kuntjoro Harimurti
Journal:  PLoS One       Date:  2021-08-12       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.